Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review

Moshe C. Ornstein\textsuperscript{a,}\textsuperscript{*,} and Jorge A. Garcia\textsuperscript{a,}b
\textsuperscript{a}Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
\textsuperscript{b}Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH, USA

Abstract

\textbf{Background:} Checkpoint inhibitors (CPI) have now been established as standard agents in the management of patients with metastatic renal cell carcinoma (mRCC). Given the unique toxicity profiles of CPIs, a detailed understanding of their incidence rate and characteristics is critical.

\textbf{Objective:} To perform a systematic review for the analysis of the incidence rate and characteristics of toxicities in mRCC patients treated with CPIs in published clinical trials.

\textbf{Methods:} A systematic search of EMBASE (Ovid) and MEDLINE (Ovid) was conducted as per PRISMA guidelines to identify prospective clinical trials of checkpoint inhibitors in mRCC. The search method involved querying for the termsrenal cell carcinoma or kidney carcinoma with any of the following: programmed cell death 1, PD-1, programmed cell death ligand 1, PD-L1, cytotoxic T-lymphocyte antigen 4, CTLA-4, immunotherapy, checkpoint inhibitor, anti-PD-1, or anti-PD-L1. Only prospective clinical trials were included.

\textbf{Results:} The systematic review yielded 9,722 records through the MEDLINE (Ovid) and EMBASE (Ovid) databases. Ultimately, five prospective clinical trials with 722 patients were selected for inclusion. The rates of any grade adverse event (AE) and grade (G) 3-4 AEs were 79.9% and 20.9%, respectively. Regarding immune-related AEs (irAEs), the most common system affected by any grade irAE was the skin (30.89%) and the most common grade 3-4 irAE was related to the hepatic system (8.23%). Rates of AEs were similar across the CPI monotherapy clinical trials.

\textbf{Conclusions:} The rates of AEs in mRCC patients treated with CPI is similar to rates in other cancers. AEs in mRCC are fairly consistent among monotherapy trials with PD-1 and PD-L1 inhibitors and as one would expect higher when CTLA-4 and PD-1 inhibitors are offered in combination.

Keywords: Renal cell carcinoma, kidney carcinoma, immunotherapy, checkpoint inhibitors, PD-1, PD-L1, CTLA-4, immune-related adverse events, toxicity

\section{INTRODUCTION}

Checkpoint inhibitor (CPI) immunotherapy, which primarily target the inherent immune inhibitory signals programmed cell death (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), have revolutionized the therapeutic landscape across many solid tumors [1–3]. A primary challenge in the era of CPI therapy revolves around the balance of efficacy and toxicity of these novel agents. Although their overall toxicity profile is favorable when compared to standard anti-cancer agents such...
as chemotherapy and targeted therapy [4–6], the immune-based mechanism of CPIs results in a novel toxicity profile that differs from traditional cytotoxic therapies [7].

The inherent immunogenic nature of renal cell carcinoma (RCC) has cemented its place at the forefront of cancer immunotherapy. Nivolumab (anti-PD-1) is currently approved for patients with metastatic RCC (mRCC) who have been previously treated with VEGF-TKI based therapy [4]. Similarly, phase III data of the combination of nivolumab and ipilimumab (anti-CTLA-4) has demonstrated overall survival (OS) superiority to a current standard of care [8]. A plethora of phase III trials are also underway investigating the use of novel combinations of CPI and targeted therapies [9–12]. A better understanding of these AEs and their management is critical for practicing physicians as the use of these novel agents is expanding across different stages of RCC.

Given the multitude of CPIs with clinical activity in mRCC, an analysis of CPI-induced toxicities is essential. To date, multiple case reports and case series have been published describing AEs related to these agents [13, 14]. In this systematic review, we evaluate the incidence rate and characteristics of toxicities in mRCC patients treated with CPI therapy in published clinical trials.

METHODS

Search methods

A systematic review of the literature was conducted according to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [15]. The PUBMED (Ovid) and EMBASE (Ovid) databases were searched up to September 1, 2017. The search method involved querying for the terms renal cell carcinoma or kidney carcinoma with any of the following: programmed cell death 1, PD-1, programmed cell death ligand 1, PD-L1, cytotoxic T-lymphocyte antigen 4, CTLA-4, immunotherapy, checkpoint inhibitor, anti-PD-1, or anti-PD-L1. The first stage was the selection of articles that included any combination of the aforementioned terms. The second stage involved identifying the year in which there were increasing mentions of checkpoint inhibitor terms in article titles (e.g., B7, CTLA-4). The year 2007 was thus selected as the starting point for article screening. Subsequent stages are outlined in Fig. 1.

Inclusion and exclusion criteria

The eligibility criteria for inclusion in the systematic review included prospective clinical trials of checkpoint inhibitors in patients with mRCC. Abstracts, systematic reviews, and review articles were excluded from the analysis. The analysis was limited to articles from January 1, 2007 through September 1, 2017.

Data extraction and outcome measures

The final articles were jointly selected by the two authors who then extracted the AE data and presented them in descriptive form. Priority was given to AEs described in each of the final articles that met selection criteria. Unless otherwise noted, every AE was described in all articles reviewed.

AEs and irAEs

Adverse Events (AEs) were extracted if they were considered “treatment-related” in the respective clinical trials. Only the most common AEs in each trial were selected for inclusion in this systematic review. Immune-related adverse events (irAEs) refer to specific AEs assumed to be driven by immune-related processes induced by the mechanism of action of CPI therapy. Specifically, skin (rash, pruritus), endocrine (hypothyroidism), gastrointestinal (diarrhea), hepatic (elevated AST and ALT), pulmonary (pneumonitis),
Table 1
Rates on AEs by clinical trial

| Phase         | Nivolumab | Nivolumab | Nivolumab | Atezolizumab | Ipilimumab + Nivolumab |
|---------------|-----------|-----------|-----------|--------------|------------------------|
|               | I (18)    | II (19)   | III (4)   | Ia (16)      | I (17)                 |
| All Gr        | 34        | 168       | 406       | 70           | 94                     |
| Gr 3-4        | 17.65%    | 11.90%    | 18.72%    | 17.14%       | 50.00%                 |
| Discontinued  | 14.71%    | 6.55%     | 7.64%     | 4.29%        | 19.15%                 |
| due to AE     |           |           |           |              |                        |
| Deaths due    | 0         | 0         | 0         | 0            | 0                      |
| to AE         |           |           |           |              |                        |
| Pneumonitis   | All Gr    | 2.94%     | 4.76%     | 3.94%        | 2.86%                  |
|               | Gr 3-4    | 0         | 0         | 1.48%        | 0                      |
|               |           |           |           |              |                        |
| Fatigue       | All Gr    | 2.94%     | 26.79%    | 33.00%       | 28.57%                 |
|               | Gr 3-4    | 0         | 0         | 2.46%        | 4.29%                  |
|               |           |           |           |              | 3.19%                  |
|               |           |           |           |              |                        |
| Rash          | All Gr    | 26.47%    | 9.52%     | 10.10%       | 14.29%                 |
|               | Gr 3-4    | 0         | 0         | 0.49%        | 0                      |
|               |           |           |           |              |                        |
| Pruritus      | All Gr    | 17.65%    | 10.12%    | 14.04%       | 11.43%                 |
|               | Gr 3-4    | 2.94%     | 0.60%     | 0            | 0                      |
|               |           |           |           |              |                        |
| Dry skin      | All Gr    | 11.76%    | 6.55%     | NR           | 8.57%                  |
|               | Gr 3-4    | 0         | 0         | NR           | 0                      |
|               |           |           |           |              |                        |
| Nausea        | All Gr    | 5.88%     | 11.90%    | 14.04%       | 12.86%                 |
|               | Gr 3-4    | 0         | 1.19%     | 0.25%        | 0                      |
|               |           |           |           |              | 1.06%                  |
| Diarrhea      | All Gr    | 17.65%    | 9.52%     | 12.32%       | 11.43%                 |
|               | Gr 3-4    | 0         | 0         | 1.23%        | 0                      |
|               |           |           |           |              | 9.57%                  |
| Elevated AST  | All Gr    | 17.65%    | 8.93%     | NR           | 2.86%                  |
| or ALT        | Gr 3-4    | 0         | 2.38%     | NR           | 2.86%                  |
|               |           |           |           |              | 21.28%                 |
| Decreased     | All Gr    | 8.82%     | 6.55%     | 11.82%       | 15.71%                 |
| appetite      | Gr 3-4    | 0         | 0         | 0.49%        | 0                      |
|               |           |           |           |              |                        |
| Arthralgia    | All Gr    | 8.82%     | 7.74%     | NR           | 14.29%                 |
|               | Gr 3-4    | 0         | 0.60%     | NR           | 0                      |
|               |           |           |           |              |                        |
| Hypothyroidism| All Gr    | 8.82%     | 5.95%     | NR           | 8.57%                  |
|               | Gr 3-4    | 0         | 0.60%     | NR           | 0                      |
|               |           |           |           |              | 2.13%                  |

NR = Not reported.

and renal (increased creatinine) irAEs were selected for inclusion.

RESULTS

The systematic review yielded 9,722 records through the MEDLINE (Ovid) and EMBASE (Ovid) databases that met the initial search criteria. Figure 1 outlines the PRISMA consort diagram, duplicates, and excluded articles. Ultimately, only five prospective clinical trials of checkpoint inhibitors in patients with mRCC were identified and selected for inclusion. These included a phase Ia trial of atezolizumab (anti-PD-L1) [16], phase I trial of combined ipilimumab/nivolumab [17], and the phase I, II, and III trials of nivolumab in mRCC [4, 18, 19].

A total of 722 patients were included in these five clinical trials. Table 1 highlights the most common AEs in each of the clinical trials and provides a comparison of these AEs across these trials. The largest of these five trials (n = 406) is the phase III trial (CheckMate025) that compared nivolumab to the m-TOR inhibitor everolimus in patients with previously treated mRCC [4]. The smallest of these trials was the phase I trial of nivolumab. This expanded phase I trial of nivolumab included a total of 296 patients with various solid tumors, of which only 34 had mRCC [20]. The original manuscript did not describe toxicity based on tumor subtype and as such the data included here are from the long-term safety data of the subset of patients with mRCC [18].

Overall, highest rates of AEs were in the phase I ipilimumab/nivolumab trial [17]. In this trial, all grade AEs and G3-4 AEs were 93.6% and 50%, respectively (Table 1). AEs were lowest in the phase II trial (All G 72.6%; G3-4 11.9%), possibly due to the various dosing cohorts in the trial of nivolumab these patients received [19]. When analyzing all trials and patients included in the systematic review (n = 722), the rates of any AE and G3-4 AEs were 79.9% and 20.9%, respectively, with only 8.8% of patients discontinuing treatment due to AEs (Table 2).

Given the expected and well-documented higher rates of AEs in patients treated with combined ipilimumab and nivolumab, Table 3 summarizes the AE
Table 2
Summary of AEs in five trials included in systematic review

|                  | All Grade | Gr 3-4 |
|------------------|-----------|--------|
| N = 772          | 617       | 161    |
| N%               | 79.92%    | 20.85% |
| Fatigue          | 268       | 16     |
| N%               | 34.72%    | 2.07%  |
| Elevated AST or ALT |
| N = 172         | 161       | 1      |
| N%               | 94.02%    | 5.98%  |
| Nausea           | 122       | 4      |
| N%               | 15.80%    | 0.52%  |
| Pruritus         | 120       | 2      |
| N%               | 15.54%    | 0.18%  |
| Diarrhea         | 113       | 14     |
| N%               | 14.64%    | 1.18%  |
| Fevers           | 28        | 1      |
| N%               | 14.14%    | 1.01%  |
| Rash             | 103       | 2      |
| N%               | 13.34%    | 0.26%  |
| Arthralgia       | 48        | 1      |
| N%               | 13.11%    | 0.30%  |
| Decreased appetite| 93       | 2      |
| N%               | 12.05%    | 0.26%  |
| Hypothyroidism   | 36        | 3      |
| N%               | 9.84%     | 0.32%  |
| Dry skin         | 21        | 0      |
| N%               | 7.72%     | 0.00%  |
| Pneumonitis      | 35        | 6      |
| N%               | 4.53%     | 0.78%  |

Discontinued due to AE | 68 (8.81%)
Deaths due to AE | 0 (0%)

1Data not reported in 1 trial. 2Data not reported in 2 trials.

Table 3
Summary of AEs, excluding ipilimumab/nivolumab clinical trial

|                  | All Grade | Gr 3-4 |
|------------------|-----------|--------|
| N = 678          | 529       | 114    |
| N%               | 78.02%    | 16.84% |
| Fatigue          | 213       | 13     |
| N%               | 31.42%    | 1.92%  |
| Nausea           | 88        | 2      |
| N%               | 12.98%    | 0.29%  |
| Pruritus         | 88        | 3      |
| N%               | 12.98%    | 0.44%  |
| Diarrhea         | 80        | 5      |
| N%               | 11.80%    | 0.74%  |
| Rash             | 76        | 2      |
| N%               | 11.21%    | 0.29%  |
| Decreased appetite| 73       | 2      |
| N%               | 10.77%    | 0.29%  |
| Fevers           | 11        | 0      |
| N%               | 10.58%    | 0.00%  |
| Elevated AST or ALT |
| N = 172         | 23        | 6      |
| N%               | 8.46%     | 2.21%  |
| Nausea           | 88        | 3      |
| N%               | 12.98%    | 0.44%  |
| Rash             | 76        | 2      |
| N%               | 11.21%    | 0.29%  |
| Arthralgia       | 26        | 1      |
| N%               | 9.56%     | 0.37%  |
| Dry Skin         | 21        | 0      |
| N%               | 7.72%     | 0.00%  |
| Hypothyroidism   | 19        | 1      |
| N%               | 6.99%     | 0.37%  |
| Pneumonitis      | 27        | 6      |
| N%               | 3.98%     | 0.88%  |

Discontinued due to AE | 50 (7.37%)
Deaths due to AE | 0 (0%)

1Data not reported in 2 trials. 2Data not reported in 1 trials.

DISCUSSION

Ever since the durable and complete responses to interleukin-2 (IL-2) in mRCC, immunotherapy has been investigated as a potential therapeutic intervention in patients with RCC [21–23]. Nivolumab was the first CPI approved in mRCC based on the phase III CheckMate-025 trial that demonstrated an OS benefit to nivolumab over everolimus in patients who received prior anti-angiogenic therapy [4]. CPIs are also poised to become a standard of care in the front-line mRCC setting, with results of a number of phase III clinical trials expected over the next few years [9–12] and with the recent results of CheckMate-214 which noted an OS benefit in intermediate and high-risk untreated mRCC patients receiving the combination of ipilimumab/nivolumab vs sunitinib [8]. An understanding of the rates and characteristics of AEs in mRCC patients treated with CPIs is thus critical.

In this systematic review, AE data from five clinical trials of CPIs in mRCC are summarized (Tables 1–3; Fig. 2). The frequency of treatment-related AEs in this systematic review of mRCC patients treated with CPIs is similar to published data of patients with melanoma who were treated with CPI therapy. In pooled analyses of melanoma patients treated with ipilimumab or nivolumab the rates of all grade AEs were 85% and 71%, respectively [24, 25]. Additionally, other systemic reviews and meta-analyses also document CPI-induced irAE rates of approximately 70–80%, with organ-specific (e.g., skin, hepatic and pulmonary among others) breakdowns similar to those in this review [24, 26, 27]. These data suggest that irAEs are likely to be driven by therapy choice rather than underlying malignancy. As such, broad guidelines developed for the management of immune-related AEs (irAE) can be implemented across disease groups (Table 4) [28–30].

Although CPI-induced AEs vary in timing of onset and severity, most are reversible with systemic therapy and multiple published guidelines exist to facilitate best therapeutic choices [29, 31–33]. A practical consideration when treating patients with CPI therapy must include an infrastructure that allows for a close monitoring of AEs. Unfortunately, there is no specific timing as when these irAEs appear to occur. Most clinical trials and pooled analyses of CPI-based therapy suggest these events occur anywhere from weeks to years after the initiation of therapy and even after therapy cessation [24, 32]. However, there is emerging evidence that suggests that the
Fig. 2. Rates of select organ-specific irAEs.

majority of irAEs occur within the first year of therapy initiation and that most will fully resolve with appropriate therapy [24, 33].

Data regarding duration of irAEs are limited in the RCC literature. However, in melanoma the data suggest that most irAEs resolve within 12 weeks of onset [34]. Similarly, although most irAEs will resolve with adequate therapy, data on resuming CPIs upon irAE resolution are lacking in RCC. In an analysis of eighty melanoma patients who developed irAEs and were rechallenged with CPI therapy following irAE resolution, 31 (39%) patients subsequently developed recurrence of initial irAE or a distinct irAE [35]. Additional data are thus needed to determine duration of irAEs and the safety of resuming CPI therapy after irAE resolution in RCC patients.

Established guidelines for the management of irAEs generally include systemic corticosteroids as the optimal primary treatment with the addition of other immunomodulatory agents such as anti-TNF-α for refractory irAEs [29, 32]. A theoretical concern regarding the use of systemic corticosteroids in patients receiving CPI-based therapy is that it could potentially mitigate and compromise the innate anti-tumor effect reestablished with CPI therapy. Fortunately, the use of systemic immunosuppressants does not appear to negatively impact outcome in CPI-treated patients [24, 25, 36]. In separate cohorts of melanoma patients treated with nivolumab or ipilimumab-treated melanoma patients, up to one-third of patients required systemic corticosteroid treatment and 10% also required an anti-TNF-α agents for irAE control. Outcomes were not negatively affected by the use of systemic immunosuppressants suggesting these agents can be used without compromising clinical outcome [24, 25].

Interestingly, clinical responses appear to be sustained for a number of patients who discontinue therapy due to irAEs. In a large cohort of ipilimumab-treated melanoma patients, 12% of patients who had their CPIs discontinued due to irAEs maintained durable disease control without requiring subsequent treatment [25]. Similar findings were noted in the CPI-treated mRCC patients. In an analysis of mRCC patients treated with CPI who discontinued therapy secondary to irAEs, 44% of patients maintained a durable partial response despite not receiving subsequent therapy, with a median time from CPI discontinuation of 20 months (range, 10–44) [37].

The predictive and prognostic significance of irAEs in patients treated with immunotherapies has become an important area of discussion. The association of irAEs and response to therapy dates back to the association of specific immune-mediated AEs (e.g., hyperthyroidism and vitiligo) and clinical response to IL-2 [38, 39]. The implication of irAEs in patients treated with CPI therapy is also well documented. A number of studies demonstrate an association between the development of irAEs and clinical response to CPI therapy, specifically with ipilimumab [31, 40–42]. In a phase II trial of ipilimumab in mRCC, the response rate was 30% in
Table 4
Management of common irAEs

| irAE                     | Gr 1                     | Gr 2                     | Gr 3                     | Gr 4                     |
|-------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Skin (rash/pruritus)    | • Continue CPI           | • Continue CPI           | • Hold CPI               | • Permanently discontinue CPI |
|                         | • Avoid sun exposure and  | • Supportive care as per | • Topical therapy as per | • IV (methyl)prednisolone |
|                         | skin irritants           | Gr 1                     | Gr 2                     | 1-2 mg/kg                |
|                         | • Topical emollients     | • Topical steroids       | • Prednisolone           |                         |
|                         | • Topical steroids (mild | (moderate strength) +/–  | 0.5-1 mg/kg with taper   |                         |
|                         | strength) +/- antihistamines |                        | over few weeks           |                         |
|                         |                          |                          | • Resume CPI with irAE   |                         |
|                         |                          |                          | resolution to Gr1 or     |                         |
|                         |                          |                          | mild Gr2                 |                         |
| Hepatotoxicity          | • Continue CPI           | • Hold CPI               | • Permanently discontinue CPI |
|                         | • Investigate other causes for hepatotoxicity | • Check LFT twice weekly | • (Methyl)prednisolone 1-2 mg/kg/d |
|                         |                          | • If Gr2 LFT elevation persists for 1-2 weeks, start prednisolone 1 mg/kg/d | • If no response within 2-3 days, add mycophenolate mofetil 500 mg-1 g BID |
|                         |                          | • Resume CPI following LFT improvement to Gr1 and steroid taper | • Consider liver biopsy |
| Gastrointestinal (diarrhea or colitis) | • Symptomatic control: fluids, loperamide, etc | • Hold CPI | • As per Gr 3 | • Consider liver biopsy |
|                         |                          | • Prednisolone 0.5-1 mg/kg or oral budesonide | • IV (methyl)prednisolone 1-2 mg/kg |
|                         |                          | • If no improvement, proceed with sigmoidoscopy/colonoscopy | • Sigmoi-
|                         |                          |                          | doscopy/colonoscopy       |                          |
| Pneumonitis             | • Consider holding CPI   | • Hold CPI               | • Permanently discontinue CPI |
|                         | • Monitor for 2-3 days   | • Rule out infection     | • Admit to hospital      | • As per Gr 3            |
|                         | • If no improvement, treat as Gr 2 | • Start prednisone 1-2 mg/kg (taper over 4-6 weeks) | • Start IV (methyl)prednisolone 2-4 mg/kg/d |
|                         |                          |                          | • Antibiotics, CT scan, consider bronchoscopy |                          |

1Management is based on ESMO guidelines (29).

patients who developed irAEs, with no responses in patients who did not develop irAEs [42]. Similarly, in a retrospective pooled analysis of 576 patients with melanoma treated with nivolumab the development of irAEs was associated with a higher objective response rate (ORR), though no PFS benefit was noted [24].

The association between clinical efficacy and irAEs has also been demonstrated in NSCLC treated with nivolumab. In a study of 134 NSCLC patients treated with nivolumab, 51% developed irAEs. The development of irAEs was statistically significantly associated with improved PFS and OS [27]. On multivariate analysis, irAEs were independently associated with improved OS. In other analyses, irAEs were predictive of improved ORR but not OS [43]. However, it is important to note that these data are retrospective in nature and such findings have not been prospectively validated. Ultimately, the association between irAE and overall survival remains unclear, though the evidence suggests that the development of irAE at the very least does not negatively impact clinical outcomes and might predict for improved outcomes.

Although this review analyzes the currently published data of prospective clinical trials with CPI in mRCC, a remark about the future of CPI in mRCC and associated toxicities is critical. As previously mentioned, multiple clinical trials evaluating the combination of CPI and targeted therapy with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are underway. Recently, preliminary data from the JAVELIN Renal 100 trial were reported. In this phase Ib trial of front-line axitinib (VEGFR TKI) in combination with the PD-L1 inhibitor avelumab, the vast majority of

M.C. Ornstein and J.A. Garcia / Checkpoint Inhibitor Toxicity in RCC
patients (92.7%) reported an avelumab-related AE, the most common of which were diarrhea and fatigue (30.9% each) [44]. A similar side effect profile was noted in the phase 1b trial of the combination of pembrolizumab and axitinib [45]. It thus appears that combination therapy of CPI and VEGFR TKI will yield a similar AE profile to each drug when administered individually. Importantly, as many of the toxicities of CPI and VEGFR TKI therapy overlap, a particular clinical challenge will be determining which therapy is responsible for a specific AE. This is especially critical as AE management (e.g., use of corticosteroids, supportive care, etc.) may differ depending on the mechanism of therapy and subsequent AE. Careful clinical attention and AE monitoring will thus be critical when treating patients with combined CPI and VEGFR TKI therapy.

Importantly, this systematic review is not without some limitations. Most notably, a variety of doses were used in the phase I and II trials of nivolumab and as such the AE profile may not reflect that of the FDA-approved doses currently used in clinical practice. Likewise, it is expected that AE rates would be higher in patients receiving ipilimumab and nivolumab given the combination therapy and known toxicity profile of ipilimumab [8, 17, 33]. To correct for this concern, the AE analysis was performed including (Table 2) and excluding (Table 3) the combined ipilimumab/nivolumab trial. Other limitations include some incomplete data reported in clinical trial manuscripts and the relatively small number of published clinical trials. Also lacking is data regarding corticosteroid type, dose, and duration of therapy. Despite these limitations, this review provides a detailed overview of rates and characteristics of CPI-related toxicities in mRCC.

**CONCLUSION**

As CPI therapy becomes increasingly integrated into the treatment of mRCC, a clear understanding of their incidence, severity and optimal management are critical. In this systematic review of published clinical trials of CPIs in mRCC, the rates of AEs in mRCC patients treated with CPI appears to be fairly similar to those observed with nivolumab and atezolizumab monotherapy and higher with combined ipilimumab and nivolumab therapy. Most irAEs are reversible with systemic corticosteroids, and neither the development of irAEs nor their treatment appears to negatively impacts clinical outcome.

**ACKNOWLEDGMENTS**

The authors are grateful to Mary Schleicher, RN, BSN, MLIS, Medical Librarian, Floyd D. Loop Alumni Library, Cleveland Clinic, for her assistance with this systematic review.

**REFERENCES**

[1] Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
[2] Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18(2):206-13.
[3] Zhang T, Xie J, Arai S, Wang L, Shi X, Shi N, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: A meta-analysis. Oncotarget 2017;8(45):73068-79.
[4] Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373(19):1803-13.
[5] Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387(10027):1540-50.
[6] Cella D, Grunwald V, Nathan P, Doan J, Dastani H, Taylor F, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: A randomised, open-label, phase 3 trial. Lancet Oncol 2016;17(7):994-1003.
[7] Costa R, Carneiro BA, Aguilik M, Rademaker AW, Pai SG, Villadlor VM, et al. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: A systematic review and meta-analysis of randomized clinical trials. Oncotarget 2017;8(5):8910-20.
[8] Escudier BJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Plimack ER, et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. 2017 ESMO Congress :Abstract LBA5.
[9] NCT02420821. A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]. 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT02420821. Accessed September 24, 2017.
[10] NCT02684006. A Study of Avelumab With Axitinib Versus Sunitinib in Advanced Renal Cell Cancer (JAVELIN Renal 101). 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT02684006. Accessed September 24, 2017.
[11] NCT02811861. Lenvatinib/Everolimus or Lenvatinib/ Pembrolizumab Versus Sunitinib Alone as Treatment
of Advanced Renal Cell Carcinoma. 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT02811861. Accessed September 24, 2017.

[12] NCT02853331. Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426). 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT02853331. Accessed September 24, 2017.

[13] Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76(1):43-50.

[14] Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: A case report and literature review. BMC Nephrol 2016;17(1):188.

[15] Mecher D, Shamseer L, Clarke M, Ghteri D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1-4053-4-1.

[16] McDermott DF, Sosman JA, Szoln M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. J Clin Oncol 2016;34(8):833-42.

[17] Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol 2017;36(26):2443-54.

[18] McDermott DF, Drake CG, Szoln M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015;33(18):2013-20.

[19] Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2015;33(13):1430-7.

[20] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-45.

[21] Fisher RJ, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(Suppl 1):S55-7.

[22] Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422-8.

[23] Mendiarrata P, Rini BI, Ornstein MC. Emerging Immunotherapy in Advanced Renal Cell Carcinoma. Urol Oncol 2017;35(12):687-93.

[24] Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2017;35(7):785-92.

[25] Horvat TZ, Adel NG, Dang TO, Montaz P, Postow MA, Callahan MK, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33(28):3193-8.

[26] Bertrand A, Kostine M, Bartemache T, Truchetet ME, Schaverbeck T. Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Med 2015;13:211-015-0455-8.

[27] Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer. JAMA Oncology 2017;Epub ahead of print (September 21 2017): http://jamanetwork.com/journals/jamaoncology/fullarticle/2654556.

[28] Hahn AW, Gill DM, Agarwal BL. PD-1 checkpoint inhibition: Toxicities and management. Urol Oncol 2017;35(12):701–707.

[29] Haanen JBA, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl 4):iv119-iv142.

[30] Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2016;2(10):1346-53.

[31] Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24(15):2283-9.

[32] Weber JS, Kahler KC, Haushold A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691-7.

[33] Szol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol 2017;35:116721985.

[34] Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol 2017;35(12):701–707.

[35] McDermott DF, Drake CG, Szoln M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol 2015;33(18):2013-20.

[36] Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2015;33(13):1430-7.

[37] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54.

[38] Fisher RJ, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000(6(Suppl 1)):

[39] Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26(33):5422-8.

[40] NCT02853331. Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426). 2017; Available at: https://clinicaltrials.gov/ct2/show/NCT02853331. Accessed September 24, 2017.

[41] Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76(1):43-50.
[40] Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome in melanoma. Curr Opin Oncol 2011;23(2):170-6.

[41] Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13(22 Pt 1):6681-8.

[42] Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30(8):825-30.

[43] Judd J, Zibelman M, Handorf E, O’Neill J, Ramamurthy C, Bentota S, et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist 2017;22(10):1232-37.

[44] Choueiri TK, Larkin JMG, Oya M, Thistlethwaite F, Martignoni M, Nathan P, et al. First-line avelumab+axitinib therapy in patients pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. J Clin Oncol (Meeting Abstracts) 2017;35:Abstr4504.

[45] Atkins MB, Plimack ER, Puzanov I, Fishman MN, McDermott DF, Cho DC, et al. Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results. ESMO Congress 2016;Abstr773.